Sort
10,766 grants matching “checkpoint inhibitor”
Mechanisms of Selective Therapeutic Synergy of PARP-inhibition and CTLA4 Blockade Engaged by Interferon-gamma in the Ovarian Tumor Microenvironment
$351,908Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2025 · CA
Targeting CDK4 and CDK6 kinases in breast cancer development
$351,879Piotr Sicinski · Dana-Farber Cancer Inst · P01 · FY2021 · CA
Targeting CDK4 and CDK6 kinases in breast cancer development
$351,879Piotr Sicinski · Dana-Farber Cancer Inst · P01 · FY2020 · CA
PROGRESSION OF T CELL LYMPHOMA LINES TO IL2 INDEPENDENCE
$351,875Thomas Jefferson University · R01 · FY2001 · CA
Novel multipronged Immunovirotherapy Approach for GBM Treatment
$351,804Evanthia Galanis · Mayo Clinic Rochester · R01 · FY2022 · CA
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer
$351,800Scott H Kaufmann · Mayo Clinic Rochester · P50 · FY2010 · CA
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade
$351,750Harriet M Kluger · Yale University · P50 · FY2018 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$351,713Raoul Tibes · New York University School Of Medicine · R01 · FY2018 · CA
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer
$351,711Xiaolin Zi · University Of California-Irvine · R01 · FY2023 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer
$351,691Weei-Chin Lin · Baylor College Of Medicine · R01 · FY2019 · CA
Inter-regulatory function of immune-modulation and angiogenesis in cancer
$351,691Gabriele Bergers · University Of California, San Francisco · R01 · FY2019 · CA
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer
$351,669Douglas G McNeel · University Of Wisconsin-Madison · P50 · FY2024 · CA
Radioimmunotherapy Combinations for B-cell Malignancy
$351,428Damian J. Green · Fred Hutchinson Cancer Center · R01 · FY2022 · CA
Project 1: Targeting Metabolic Dependencies in PDAC
$351,368Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2020 · CA
Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
$351,245Lingtao Jin · University Of Texas Hlth Science Center · R01 · FY2025 · CA
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity
$351,098David C Linehan · University Of Rochester · R01 · FY2020 · CA
Project 1: Targeting Metabolic Dependencies in PDAC
$351,015Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2019 · CA
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
$350,997Scott Hiebert · Vanderbilt University · R01 · FY2013 · CA
The Role of Egfl6 in Tumor Immunity
$350,974Sandra Cascio · Magee-Women'S Res Inst And Foundation · R01 · FY2023 · CA
The Role of ZEB1 in promoting therapeutic resistance through its interaction with 53BP1Â
$350,960James M Larner · University Of Virginia · R01 · FY2024 · CA
Diacylglycerol kinase regulation of airway smooth muscle functions
$350,959Deepak A Deshpande · Thomas Jefferson University · P01 · FY2025 · HL
Mechanisms of PIDDosome Signaling, a p53-Independent Apoptotic Response to DNA Damage
$350,852Samuel Sidi · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · CA
Kinetochore-Microtubule Interactions in Fission Yeast
$350,727J Richard McIntosh · University Of Colorado · R01 · FY2007 · GM
Genome-wide mapping and characterization of exitrons in human cancer
$350,705Rendong Yang · Northwestern University At Chicago · R01 · FY2023 · CA
Antitumor-Antibiotics from Marine Microorganisms
$350,629William Fenical · University Of California, San Diego · R37 · FY2013 · CA